Clinical Trial: CINC280AUS12

Trial Status: Open
Disease Type: Lung
Trial ID CINC280AUS12

A Phase 2 Trial of Neoadjuvant and Adjuvant Capmatinib in Participants with Stages IB-IIIA, N2, and Selected IIIB (T3N2 or T4N2) NSCLC with MET Exon 14 Skipping Mutation or High MET Amplification

5 Locations


Alexandria Office

Arlington Office

Fairfax Office

Loudoun Office

Gainesville Office

Learn More About This Trial

Other Relevant Trials
Trial ID NAV-1104
Sponsor ID Navire Pharma

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

1 Location
Sponsor ID Arri Vent BioPharma

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

1 Location